Loading...
Kairos Pharma, Ltd.
KAPA•AMEX
Healthcare
Biotechnology
$0.57
$0.03(5.92%)
Kairos Pharma, Ltd. (KAPA) Stock Overview
Explore Kairos Pharma, Ltd.’s financial performance, market position, analyst ratings, and future outlook.
Stats data is not available for KAPAStats details for KAPA are currently unavailable. We're actively monitoring for updates and will publish them as soon as they’re released. Please check back again shortly.
Analyst Recommendations
Strong Buy
0
Buy
1
Hold
0
Sell
0
Strong Sell
0
Price Targets
Low$0.00
Average$0.00
High$0.00
Company Profile
Kairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company that develops therapeutics for cancer patients. Its therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. Kairos Pharma, Ltd. was formerly known as NanoGB13, Inc. and changed its name to Kairos Pharma, Ltd. in July 2016. The company was incorporated in 2013 and is based in Los Angeles, California.
CEO
Dr. John S. Yu M.D., Ph.D.
Employees
1
Headquarters
2355 Westwood Blvd., Los Angeles, CA
Founded
2024